Saxenda vs Rybelsus (Being Discontinued in the US): Approved for Weight, or Not

Saxenda (liraglutide, Novo Nordisk) vs Rybelsus (oral semaglutide, Novo Nordisk)

Last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

The decisive fact is the label. Saxenda has been approved for weight management since December 2014, and for ages 12 and up since December 2020. Rybelsus is approved only for adults with type 2 diabetes (for glucose control since September 2019, and now also for cardiovascular risk reduction), so weight use is off-label. Saxenda is a daily injection listing at well over $1,000. Rybelsus is being discontinued in the US; its replacement, Ozempic tablets, costs $149–$299 a month self-pay. Both have been overtaken by the weekly drugs and by the oral semaglutide approved for weight, the Wegovy tablet.

Side-by-side comparison

Saxenda vs Rybelsus, side by side
FieldSaxendaRybelsus
FDA-approved for weight lossYes (Dec 2014 adults; Dec 2020 ages 12+)No (T2D only, Sept 2019)
Pivotal weight-loss data-8.0% TBWL at 56 wk (SCALE Obesity)-4.4 kg at 26 wk vs liraglutide 1.8 mg -3.1 kg, in type 2 diabetes (PIONEER 4)
RouteSubcutaneous injectionOral tablet (fasting)
Dosing frequencyOnce dailyOnce daily
Administration protocolInject any time of day, with or without foodFasting, 4 oz water, wait 30 min before food/drink/other meds
Maintenance dose3.0 mg SC daily7 mg or 14 mg PO daily
NovoCare cash price (US)~$1,349/month$149–$299/mo self-pay as Ozempic tablets, its US replacement
Boxed warningThyroid C-cell tumors (MTC, MEN 2)Thyroid C-cell tumors (MTC, MEN 2)
Most common AENausea ~39%Nausea ~20%
Pediatric approvalAges 12+ (since Dec 2020)Adults only

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Saxenda — liraglutide

from $149 /mo

5 sellers publish a standing price. This is the lowest of all 5; the median is $160 a month.

Where to get liraglutide — a selection of sellers, not a price ranking

Rybelsus — oral semaglutide

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Saxenda or Rybelsus?

Saxenda recorded Yes (Dec 2014 adults; Dec 2020 ages 12+); Rybelsus recorded No (T2D only, Sept 2019). These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.

Are Saxenda and Rybelsus the same drug?

No. Saxenda is liraglutide and Rybelsus is oral semaglutide — different molecules. Results with one do not predict results with the other.

Is Saxenda or Rybelsus cheaper?

On the manufacturers' own cash pricing: Saxenda at ~$1,349/month, Rybelsus at $149–$299/mo self-pay as Ozempic tablets, its US replacement. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

How is each one taken?

Saxenda: Once daily. Rybelsus: Once daily. Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are liraglutide from $149 a month and oral semaglutide from $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Saxenda to Rybelsus?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity) N Engl J Med. 2015. PMID: 26132939.
  2. 2.Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Lancet. 2019. PMID: 31186120.
  3. 3.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
  4. 4.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98

See the full drug-vs-drug verdict index or provider rankings.